Boundless Bio Inc. – Material Contracts Watch

from S-4/A 17 pages Shiva Fritsch [***] Dear Shiva, on Behalf of Serapha Bio, Inc. (The “Company”) We Are Pleased to Offer You (“You” or the “Executive”) Employment With the Company Based on the General Terms That Are Outlined in This Letter

from S-4/A 17 pages Nina Hunter [***] Dear Nina, on Behalf of Serapha Bio, Inc. (The “Company”) We Are Pleased to Offer You (“You” or the “Executive”) Employment With the Company Based on the General Terms That Are Outlined in This Letter

from S-4/A 17 pages Wes Miller [***] Dear Wes, on Behalf of Serapha Bio, Inc. (The “Company”) We Are Pleased to Offer You (“You” or the “Executive”) Employment With the Company Based on the General Terms That Are Outlined in This Letter

from S-4 17 pages Daphne Karydas [***] Dear Daphne, on Behalf of Serapha Bio, Inc. (The “Company”) We Are Pleased to Offer You (“You” or the “Executive”) Employment With the Company Based on the General Terms That Are Outlined in This Letter

from S-4 17 pages Rtw Investments 40 10th Avenue, 7th Floor New York, Ny 10014 WWW.RTWFUNDS.com

from S-4 14 pages Form of Indemnification Agreement

from S-4 14 pages Rtw Newco10, Inc. 2026 Equity Incentive Plan

from S-4 59 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That Registrant Treats as Private or Confidential Exclusive License Agreement by and Between Yoltech Therapeutics Co., Ltd and Rtw Newco10 Inc. Dated June 12, 2026

from DRS 17 pages Rtw Investments 40 10th Avenue, 7th Floor New York, Ny 10014 WWW.RTWFUNDS.com

from DRS 14 pages Form of Indemnification Agreement

from DRS 14 pages Rtw Newco10, Inc. 2026 Equity Incentive Plan

from DRS 59 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That Registrant Treats as Private or Confidential Exclusive License Agreement by and Between Yoltech Therapeutics Co., Ltd and Rtw Newco10 Inc. Dated June 12, 2026

from 10-Q 15 pages You Are Currently a Party to an Amended and Restated Employment Offer Letter With Boundless Bio, Inc. (The “Company”) Dated April 2, 2024 (The “Prior Agreement”). as You Know, on June 23, 2026, the Company Entered Into an Agreement and Plan of Merger and Reorganization (The “Merger Agreement”) With Serapha Bio, Inc., a Delaware Corporation (“Serapha”), and Boulder Merger Sub Corp., a Delaware Corporation and Wholly-Owned Subsidiary of the Company (“Merger Sub”). Upon the Terms and Subject to the Satisfaction of the Conditions Described in the Merger Agreement, Merger Sub Will Be Merged With and Into Serapha, With Serapha Surviving as a Wholly Owned Subsidiary of the Company (The “Merger”). You and the Company Hereby Agree to Amend and Restate the Prior Agreement to Memorialize the Terms of Your Continued Employment With the Company, as Provided in This Amended and Restated Employment Letter Agreement (This “Amended Agreement”), Effective as of July 1, 2026 (The “Effective Date”)

from 10-Q 14 pages You Are Currently a Party to an Amended and Restated Employment Offer Letter With Boundless Bio, Inc. (The “Company”) Dated March 5, 2024 (The “Prior Agreement”). as You Know, on June 23, 2026, the Company Entered Into an Agreement and Plan of Merger and Reorganization (The “Merger Agreement”) With Serapha Bio, Inc., a Delaware Corporation (“Serapha”), and Boulder Merger Sub Corp., a Delaware Corporation and Wholly-Owned Subsidiary of the Company (“Merger Sub”). Upon the Terms and Subject to the Satisfaction of the Conditions Described in the Merger Agreement, Merger Sub Will Be Merged With and Into Serapha, With Serapha Surviving as a Wholly Owned Subsidiary of the Company (The “Merger”). You and the Company Hereby Agree to Amend and Restate the Prior Agreement to Memorialize the Terms of Your Continued Employment With the Company, as Provided in This Amended and Restated Employment Letter Agreement (This “Amended Agreement”), Effective as of July 1, 2026 (The “Effective Date”)

from 10-Q 8 pages Severance Agreement and Release of All Claims

from 10-Q 8 pages Severance Agreement and Release of All Claims

from 10-Q 8 pages Severance Agreement and Release of All Claims

from 8-K 26 pages Registration Rights Agreement

from 8-K 41 pages Securities Purchase Agreement

from 8-K 14 pages Company Stockholder Support Agreement